Cx Precision Medicine
- Diagnostics
- Medical device or technology
- Synthesis, analytic, diagnostic services
CxPM is pairing blood-based diagnostics and AI/Machine learning to rule out neurodegenerative diseases in age-appropriate patients with possible early symptoms at the primary care level. Our first test, NeuroFirstTM Memory, is the first and only blood test with results correlated to clinically defined Alzheimer’s Dementia
and appropriate for primary care, reducing referrals to expensive secondary care and providing a valuable, easy-to-use tool for the 50% of primary care physicians who do not perform cognitive assessments. Unlike
amyloid/tau tests, which are correlated to amyloid pathology, CxPM’s test correlates to cognitive function associated with Alzheimer’s Disease based on neuropsychological tests. Our underlying technology is licensed out of academia and built with over $250M in NIH funding. NeuroFirstTM Memory will launch on a limited basis as an LDT this year. CxPM also has experience identifying sub-types of responders in both Alzheimer's and Parkinson's trials.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}